Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Penile Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Lung Neoplasms 1

Interventions

Cisplatin 6pembrolizumab 5fludarabine 5Nivolumab 5Cyclophosphamide 5aldesleukin 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Ifosfamide 4Radiotherapy 3Ipilimumab 3fludarabine phosphate 2entinostat 2cabozantinib 2avelumab 2aflibercept 2Specimen Handling 2CTLA-4 Antigen 2Biopsy 2Adoptive Transfer 2vinflunine 1toripalimab 1rocakinogene sifuplasmid 1ripretinib 1oncogene protein E7, Human papillomavirus type 16 1niraparib 1nimotuzumab 1lenvatinib 1enfortumab vedotin 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Penile Neoplasms × BAY 1895344 × Genitourinary × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡